Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) (SPEQUA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04328181
Recruitment Status : Not yet recruiting
First Posted : March 31, 2020
Last Update Posted : March 31, 2020
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.

Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints


Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Coronary Artery Disease Parenchymatous; Pneumonia Kidney Stone Inner Ear Disease Brain Stroke Joint Diseases Diabetes Adrenal Incidentaloma Hyperaldosteronism Macroadenoma Interstitial Lung Disease Intracranial Arteriovenous Malformations Device: Spectral Photon Counting Computed Tomography (SPCCT) Device: DECT (Dual Energy CT) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
Estimated Study Start Date : September 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2022


Arm Intervention/treatment
Experimental: SPCCT and standard DECT
Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
Device: Spectral Photon Counting Computed Tomography (SPCCT)

For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:

  • Tube potential 120 kVp;
  • Tube current time product of 150 mAs;
  • Gantry revolution time 0.33 s;
  • Automatic exposure control (angular and longitudinal) combined xyz-axis;
  • Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;

Device: DECT (Dual Energy CT)

The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:

  • Base platform : iCT scanner
  • Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp
  • Tube current (mA) : 10 - 300
  • Spatial Resolution : > 30 lp/cm, ≤ 250 µm
  • Z-coverage isocenter (mm) : 20 mm
  • FOV (mm) : 500
  • Minimum rotation time : 0.33 s/rotation
  • Acquisition modes : Axial, Helical, Step & Shoot




Primary Outcome Measures :
  1. quality of the images [ Time Frame: Day 8 ]
    A single four-point scale will be used (1: unacceptable, 2: usable under limited conditions, 3: probably acceptable, 4: fully acceptable) based on the European guidelines on quality criteria for computed tomography


Secondary Outcome Measures :
  1. Diagnostic confidence graded [ Time Frame: Day 8 ]
    The diagnostic confidence grade will be calculated on a four-point scale (1: insufficient, 2: poor, 3: average, 4: good).

  2. Subjective image quality graded [ Time Frame: Day 8 ]
    It will be calculated on a five-point scale (1: poor, 2: fair, 3: average, 4: good, 5: excellent) for each following criterion: noise, artifacts and sharpness.

  3. CT Dose Index volumic (CTDIvol) [ Time Frame: Day 8 ]

    To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

    The CTDI is an estimation of the dose delivered to the organs for each acquired section that is based on acquisition parameters of a water phantom with a 32 cm diameter. The value is expressed in milligray (mGy).


  4. Dose Length Product (DLP) [ Time Frame: Day 8 ]

    To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

    The DLP is obtained as follows: CTDI * length of body explored = value in mGy.cm.


  5. Equivalent dose (mSv) [ Time Frame: Day 8 ]

    To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

    The equivalent dose is obtained by multiplying the DLP to the specific organ conversion factor.


  6. Quantitatively image quality : Noise [ Time Frame: Day 8 ]
    The noise by selecting regions of interest (ROI) will calculated.

  7. Quantitatively image quality : Density [ Time Frame: Day 8 ]
    The density (HU) by selecting regions of interest (ROI) will calculated.

  8. Quantitatively image quality : contrast-to-noise ratio [ Time Frame: Day 8 ]
    The contrast-to-noise ratio (CNR) by selecting regions of interest (ROI) will calculated.

  9. Depiction of anatomical structures of interest [ Time Frame: Day 8 ]
    Depiction of anatomical structures of interest will be graded on a four-point scale (1: visualization just possible, 2: unclear borders but different structures already visible, 3: very good visualization, well-defined anatomy, 4: perfect delineation of anatomy).

  10. Radiation dose [ Time Frame: Day 8 ]
    An average radiation dose delivered to the patients for each clinical application will be calculated.

  11. Statistical comparison between SPCCT and DECT [ Time Frame: Day 8 ]
    Statistical comparison between SPCCT and DECT will be performed over all images and anatomical structures globally and also for each clinical application of interest.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients presenting following one of following medical conditions:

    1. Asymptomatic type 1 or 2 diabetes as regard to cardiovascular risks
    2. Diabetic foot ulcer
    3. Adrenal glands lesions: Adrenal incidentaloma or hyperaldosteronism or macroadenoma
    4. Urinary stone(s)
    5. Known Coronary artery disease: Stent imaging or control of calcified plaques
    6. Diffuse Interstitial Lung Diseases: Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Ground Glass Opacification, Chronic Thromboembolic Pulmonary Hypertension
    7. Conductive hearing loss
    8. Brain stroke (late or post thrombectomy)
    9. Intracranial arteriovenous malformation treated with coils or Onyx
    10. Joints diseases in haemophilia
  • Patient has accepted to participate to the study and has signed the written consent;
  • Pre-menopausal women only: Negative urinary pregnancy test on the day of imaging before the administration of study drug;
  • Patient is affiliated to the French social security

Exclusion Criteria:

  • Contraindication to the use of iodine containing contrast media (including subjects with suspicion for/or known to have NSF) (if injection);
  • History of severe allergic or anaphylactic reaction to any allergen including drugs and contrast agents (as judged by the investigator, taking into account the intensity of the event);
  • History of delayed major or delayed cutaneous reaction to Iomeron injection
  • Estimated Glomerular Filtration Rate (eGFR) value < 30 mL/min/1.73 m2 derived from a serum creatinine result within 1 month before the imaging for examinations with contrast agent.
  • Any subject on hemodialysis or peritoneal dialysis;
  • Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery);
  • Pregnant or nursing (including pumping for storage and feeding);
  • Patient under guardianship, curatorship or safeguard of justice.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04328181


Contacts
Layout table for location contacts
Contact: Philippe DOUEK, Pr 04 72 07 18 83 ext +33 douek@creatis.insa-lyon.fr
Contact: Adeline MANSUY 04 72 11 51 70 ext +33 adeline.mansuy@chu-lyon.fr

Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT04328181    
Other Study ID Numbers: 69HCL19_0486
ID-RCB ( Other Identifier: 2019-A02945-52 )
First Posted: March 31, 2020    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hospices Civils de Lyon:
Diagnostic
SPCCT
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenocortical Adenoma
Joint Diseases
Lung Diseases
Lung Diseases, Interstitial
Ear Diseases
Labyrinth Diseases
Labyrinthitis
Intracranial Arteriovenous Malformations
Kidney Calculi
Coronary Artery Disease
Diabetic Foot
Arteriovenous Malformations
Foot Ulcer
Hyperaldosteronism
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Respiratory Tract Diseases
Diabetic Angiopathies
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies